News | April 19, 2025
GSK’s blenrep combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Subscribe To Our Newsletter & Stay Updated
